We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Mirati's (MRTX) Adagrasib Gets Breakthrough Therapy Status
Read MoreHide Full Article
Mirati Therapeutics, Inc. announced that adagrasib — an investigational, highly selective, and potent oral small-molecule inhibitor of KRAS G12C — has been granted the Breakthrough Therapy designation (BTD) by the FDA for the treatment of non-small cell lung cancer (NSCLC) patients with KRASG12C mutation following prior systemic therapy.
The designation was supported by preliminary data from the registrational phase I/II study — KRYSTAL-01 — that is evaluating the candidate in advanced NSCLC patients whose disease has progressed following treatment with immunotherapy and/or chemotherapy. The company plans to file a new drug application to the FDA seeking approval for adagrasib in the second half of this year for the treatment of KRAS G12C mutated NSCLC.
Please note that the Breakthrough Therapy designation is granted to medicines being evaluated for serious conditions where early clinical evidence indicates the potential for substantial improvement over available therapy. This designation increases the likelihood of a potential approval of adagrasib.
Last month, the company collaborated with QIAGEN N.V. (QGEN - Free Report) to accelerate the development of a tissue-based KRAS companion diagnostic that detects KRAS G12C mutation in NSCLC and colorectal cancer (CRC).
The stock has underperformed the industry so far this year. It has declined 25.2% against the industry’s increase of 0.4%.
Image Source: Zacks Investment Research
Apart from NSCLC, the company is also developing adagrasib in combination with Merck’s (MRK - Free Report) Keytruda (pembrolizumab) or afatinib for treating NSCLC patients. It is also developing a combination of adagrasib and Eli Lilly’s (LLY - Free Report) Erbitux (cetuximab) for treating CRC.
The company has another candidate — sitravatinib — in its pipeline. The candidate is being developed in combination with Bristol-Myers’ Opdivo for NSCLC and with Beigene’s anti-PD-1 checkpoint inhibitor candidate, tislelizumab, in a number of advanced solid tumors.
Both adagrasib and sitravatinib are being evaluated in multiple mid- to late-stage studies. Data from these studies will be key catalysts for growth of the company’s shares, going forward.
Bitcoin, Like the Internet Itself, Could Change Everything
Blockchain and cryptocurrency has sparked one of the most exciting discussion topics of a generation. Some call it the “Internet of Money” and predict it could change the way money works forever. If true, it could do to banks what Netflix did to Blockbuster and Amazon did to Sears. Experts agree we’re still in the early stages of this technology, and as it grows, it will create several investing opportunities.
Zacks’ has just revealed 3 companies that can help investors capitalize on the explosive profit potential of Bitcoin and the other cryptocurrencies with significantly less volatility than buying them directly.
Image: Bigstock
Mirati's (MRTX) Adagrasib Gets Breakthrough Therapy Status
Mirati Therapeutics, Inc. announced that adagrasib — an investigational, highly selective, and potent oral small-molecule inhibitor of KRAS G12C — has been granted the Breakthrough Therapy designation (BTD) by the FDA for the treatment of non-small cell lung cancer (NSCLC) patients with KRASG12C mutation following prior systemic therapy.
The designation was supported by preliminary data from the registrational phase I/II study — KRYSTAL-01 — that is evaluating the candidate in advanced NSCLC patients whose disease has progressed following treatment with immunotherapy and/or chemotherapy. The company plans to file a new drug application to the FDA seeking approval for adagrasib in the second half of this year for the treatment of KRAS G12C mutated NSCLC.
Please note that the Breakthrough Therapy designation is granted to medicines being evaluated for serious conditions where early clinical evidence indicates the potential for substantial improvement over available therapy. This designation increases the likelihood of a potential approval of adagrasib.
Last month, the company collaborated with QIAGEN N.V. (QGEN - Free Report) to accelerate the development of a tissue-based KRAS companion diagnostic that detects KRAS G12C mutation in NSCLC and colorectal cancer (CRC).
The stock has underperformed the industry so far this year. It has declined 25.2% against the industry’s increase of 0.4%.
Apart from NSCLC, the company is also developing adagrasib in combination with Merck’s (MRK - Free Report) Keytruda (pembrolizumab) or afatinib for treating NSCLC patients. It is also developing a combination of adagrasib and Eli Lilly’s (LLY - Free Report) Erbitux (cetuximab) for treating CRC.
The company has another candidate — sitravatinib — in its pipeline. The candidate is being developed in combination with Bristol-Myers’ Opdivo for NSCLC and with Beigene’s anti-PD-1 checkpoint inhibitor candidate, tislelizumab, in a number of advanced solid tumors.
Both adagrasib and sitravatinib are being evaluated in multiple mid- to late-stage studies. Data from these studies will be key catalysts for growth of the company’s shares, going forward.
Mirati Therapeutics, Inc. Price
Mirati Therapeutics, Inc. price | Mirati Therapeutics, Inc. Quote
Zacks Rank
Mirati currently has a Zacks Rank #4 (Sell).
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Bitcoin, Like the Internet Itself, Could Change Everything
Blockchain and cryptocurrency has sparked one of the most exciting discussion topics of a generation. Some call it the “Internet of Money” and predict it could change the way money works forever. If true, it could do to banks what Netflix did to Blockbuster and Amazon did to Sears. Experts agree we’re still in the early stages of this technology, and as it grows, it will create several investing opportunities.
Zacks’ has just revealed 3 companies that can help investors capitalize on the explosive profit potential of Bitcoin and the other cryptocurrencies with significantly less volatility than buying them directly.
See 3 crypto-related stocks now >>